About the new international journal

Translational and Regulatory Sciences (TRS)

With the coope ration of the Japan Age ncy for Me dical Re se arch and De ve lopme nt (AMED), The Unive rsity ofTokyo, the Graduate School of Agriculture and Life Sciences, and the National Institutes of Biomedical Innovation,
Health and Nutrition (NIBIOHN), etc., we have now established an e-Journal named Translational and Regulatory
Sciences (TRS). The Pharmace uticals and Me dical De vice s Age ncy (PMDA), the National Institute of He alth
Sciences (NIHS), and Japan Pharmaceutical Manufacturers Association (JPMA) will also support TRS.
TRS is an international peer-reviewed e-Journal with an entirely new concept of handling Translational Sciences andRegulatory Sciences. Translational Sciences (TS) is different from Translational Research (TR). TS is a division of
Biomedical Sciences designed to maintain the efficiency and speed of TR. It is our hope that TS will pioneer medical
research that supports and leads to further developments in TR.
In recent years, medications have diversified from small-molecule drugs to include medium-molecule drugs,
nucleic acid drugs, and even antibody drugs. In addition, tools such as medical devices and cell therapies including
iPS and stem cells are also becoming increasingly diverse. Evaluating the safety, accuracy, and efficiency of researchin the field of Regulatory Sciences (RS) is highly important. For the purpose, open discussion and fusion within thefield of drug discovery research is essential. TRS is a journal with the objective to provide “the place for the forum”.
In addition, we hope that the articles published in TRS will operate as a strict evaluator of the efficacy and safety of
new drugs coming into the market in and around the country.
TRS is not an international agency magazine of a certain academic society. As previously mentioned, academic
institutions, national research institutes, and private companies will continue to support and expand TRS, which in turnwill lead to the establishment of academic societies throughout Japan, allowing it to lead the field in the near future.
We are waiting for numerous original papers, columns, and review posts.

From the Editorial Board

1. Purpose of TRS

Translational science is a field of biomedical sciences. Translational science is different from translational research andtranslational medicine. Translational research is wide and encompasses everything between non-clinical and developmental
research, and aims to establish the results obtained in basic research in the academe as new medical technology/medicine
that can be used clinically. In translational medicine, research results obtained in translational research are applied in clinical
trials and le ad to the actual clinical se tting. Me anwhile , translational scie nce is the unde rlying re se arch of translationalre se arch, and it re fe rs to basic re se arch that has the pote ntial to advance to translational re se arch in the future and that
contributes to the development of regulatory science.
Regulatory science in the de ve lopme nt of
medicine indicates the basic and applied sciences thatrefer to the establishment of test studies to ensure thequality, safety, and effectiveness of pharmaceuticals
and me dical de vice s, and to e stablish e valuations,prediction, and judgment. Regulatory science is ascientific field that is also required for the inspection,
safety evaluation, manufacturing control, and quality
control of pharmace uticals and me dical de vice s, aswell as for inspection and internal audit, such as Good
Manufacturing Practice (GMP), Good Laboratory
Practice (GLP), and Good Clinical Practice (GCP).
Translational science and regulatory science

have quickly e volve d ove r the last de cade , and areboth interdisciplinary and multidisciplinary, depending

2

upon a large number of basic and applied scientific disciplines. Translational science and regulatory science are mutually
involved in a complex manner. Therefore, both have to progress scientifically with respect to each other.
Translational and Regulatory Sciences (TRS) creates a new platform for launching new ideas, not only for industry andregulatory authorities but also by members of the academe who want to contribute to the better use of their research activities
within medical aspects. Thus, TRS significantly impacts the abilities of these communities to bring new medicines andmedical devices to patients in need.
The expected effect of TRS is that industry, academic, and government experts will harmonize their efforts on equal
footing and will promote academic progress and dissemination regarding the regulatory science of pharmaceuticals, medical
devices, and related aspects using this journal.

2. Spectrum of TRSa) Original article (Full paper, Short communication)
The journal adopts a peer-review system and aims for publishing high-quality research.
The translational and regu latory science (TRS) spectru m represents each stage of research along the path from thebiological basis of health and disease to interventions, inclu ding core technologies and clinical innovation. Throu ghthese stages, innovative methods and approaches that improve and accelerate the development of new pharmaceuticals
and medical devices for translational and regulatory sciences are created and tested. TRS also accepts papers on toxicity
evaluation and basic data necessary for new drug applications.
b) Review
Post type: adopts a peer-review system
Request type: by the planning and recommendation of the editorial committeec) News
Introduces highly promising and epoch-making practical cases and new drugs
Introduces new regulations
Introduces new facilities for drug discovery of the worldd) Platform
The journal invites opinion from both the translational science and regulatory science sides regarding problems anddirection in current and future drug discovery research worldwide.

3. Scope of TRS
Translational Sciences Section● Establishment of new technology for drug discovery and drug toxicity evaluation: assay system(including highthroughput screening (HTS), antibody, cell line, diagnostic marker, drug delivery system, target identification andvalidation, de-risking therapeutic development, cell therapy, regenerative medicine, gene therapy, and so on● Establishment of new animal models of human diseases● Identification of new target molecules and/or signaling in human diseases● Translational clinical sciences in experimental small animals, from dogs and monkeys to humans● New technology, method, and/or theory for analytical chemistry, early- or late-stage drug repurposing, compound
library management, collaboration and partnerships, data transparency and sharing, patient and contact registries
Regulatory Sciences Section● Evaluation of efficacy of new drugs before approval● Evaluation of toxicity of new target molecules● Proof of safety of new target compounds, antibodies, drug delivery systems● New method to identify toxicity using new technology● New concepts in benefit/risk assessment, submission and approval strategies, patient involvement, and ethical aspects● New standards and approaches to facilitate sound and transparent regulatory decision-making regarding drugs andmedical devices● New standards, concepts, proposals, and/or regulations for gene therapy, cell therapy, and regenerative medicine

3

Mission of AMED iD3 Catalyst Unit

Aspiring to be a Navigator of
Innovative Drug
Discovery Development
Three years have passed since the Japan Agency for Medical Research and Devel opment (AMED) wasestablished. The name and roles of AMED are becoming familiar among people who engage in medical researchin academia and industry, but are still not well-recognized among patients and the general public. Prof. Makoto
Suematsu, President of AMED, often encourages AMED staff with the message that the mission of AMED is todeliver the results of medical innovation to patients and their families in the earliest way. He demonstrates pridein our work, which encompasses more than just funding, and is determined to meet the expectation of patients
who are awaiting the new medical therapies that follow from medical research in timely manner. His words
essentially represent the mission to be fulfilled and the determination shared by all AMED staff.
AMED offers various programs to support drug development. Among them, the Drug Discovery Support
Network, has unique qual ities, as experienced AMED Science Coordinators, as an advisor, accompany
researchers and collaborate to translate the results of research into clinical application. In the early phase of drug
development, academic researchers and research projects need a wide range of support. More specifically, froma drug development perspective, advice on many aspects is provided, including what type of studies should be
conducted, the provision of technology and archives of public research organizations and those from the private
sector, and the collection and validation of necessary data by using the data from prospective seeds from academic
researchers, and consideration of the strategic plan of intellectual property management and industry-university
collaborations. Throughout the course of our support, there are situations in which we have to be daring andsuggest ideas outside of the researchers’ comfort zone. Such suggestions are based on our mission to “deliver the
results of the scientific research to patients and their families in the earliest way” with limited resources. In thissituation, we try to explain reasons for our judgement and carefully suggest possible alternatives personalized
to each researcher. I bel ieve that discussions l ike that are very important for innovative drug discovery anddevelopment (iD3).
It takes a decade and the collective enthusiasm and expertise of many people to market a single new drug.
We wish to navigate prospective seeds to patients in the best way to avoid deadlocks during this process. As
navigators who “envision and go forward with researchers”, iD3 coordinators and all AMED staff members
will continue to contribute to innovative drug discovery and development through this Drug Discovery Support
Network project.

Noriatsu Kono
Managing Director,
Department of Innovative Drug Discovery and Development, Japan Agency for Medical Research and Development

4

1. About the Catalyst Unit
The Catalyst Unit is one of the “Drug Discovery & Development” program units created by the Department of
Innovative Drug Discovery and Development (iD3) of the Japan Agency for Medical Research and Development(AMED). AMED iD3 has constructed eig ht units in the Infrastructure Prog ram for Drug Discovery Seeds
Development to create a bridge between valuable resources in private sector and academic research organizations(ARO) to further drug development research. The goals of the program are strengthening support network anddriving force for innovative drug discovery and development. The Catalyst Unit is responsible for public relations
activities, such as sharing information among the eight AMED iD3 Units, and providing a place for transmitting
information, presenting problems, and creating discussion for stakeholders in academia, industry, and regulatory
agencies.
2. The world situation surrounding drug development
To enhance development of drugs, medical devices, and regenerative medical products, various scientifictechnologies are necessary. Recently, regulations of review medical products have changed significantly inorder to accommodate new types of medicines, including antibody drugs, nucleic acid drugs, and accelerated
implementation of iPS cells. Under these circumstances, further advancement of “Translational Science” isessential for the development of research in medical areas. Here, the term translational science subsumes the
exploratory technology that bridges basic research into practical use of drugs, medical devices, and regenerative
medical products, and scientific technology that evaluate efficacy and toxicity. In other words, it is of great
importance to proactively identify biomedical science research conducted by academia that may lead to translational
research and translational medicine. In addition, promotion of “Regulatory Science” is also mandatory to optimize
the advancement of science and technolog y in accordance with reg ulations. Therefore, in Japan, cooperation
with Ministry of Health, Labour and Welfare (MHLW), Pharmaceuticals and Medical Devices agency (PMDA),
pharmaceutical companies, and medical engineering companies are critical. In addition, it is necessary to createa place where members of the global community of researchers into translational science and regulatory sciencecan share their research results and inspire each other. The National Institutes of Health (NIH) and National
Center for Advancing Translational Sciences (NCATS) in the US and the Innovative Medicines Initiatives (IMI)
in Europe work on large national projects similar to AMED in Japan; therefore, harmonization with such overseasorganizations is also necessary.
3. Aim and activities of the Catalyst Unit
The Catalyst Unit is operated by the Department of Veterinary Pharmacolog y, of the Graduate School ofAg ricultural and Life Sciences, University of Tokyo. The mission of the unit is to be an information hub todisseminate outcomes of research into translational science and regulatory science by projects granted by AMED,
as well as research outcomes from overseas organizations by means of the international e-journal “Translational
and Regulatory Sciences”, which will be released in 2019. TRS is a peer reviewed international journal but
not journal for one academic society. Therefore, all researchers working in not only the academia but also
pharmaceutical companies, medical equipment manufactures and National Research Institutes are required toback up the TRS with full strength.
At the same time, the Catalyst Unit would also like to collaborate with organizations in academia, industry,and regulators by hosting international symposia and public relations activities through this website. I appreciate
your understanding and cooperation for our activities.

Masatoshi Hori, Ph.D., D.V.M.
Head of Catalyst Unit
Professor of Laboratory of Veterinary Pharmacology
Graduate School of Agriculture and Life Sciences, The University of Tokyo

5

TRANSLATIONAL AND REGULATORY SCIENCES
Instructions for Authors(Brief version)

Please visit our website https://cutrs.jp for whole instructions
Aim
The aim of this international open access journal, Translational andRegulatory Sciences (TRS), is to create a new platform for launching new
ideas, by not only industry and regulatory authorities but also members of
the academe who want to contribute to better use of their research activities
within the medical realm. Thereby, the journal aims to render a significant
impact on the abilities of those communities to bring new medicines andmedical devices to patients in need. An expected effect of TRS is thatexperts from the industry, academe, and government will harmonize
their efforts on equal footing and will promote academic progress anddissemination regarding the regulatory science of pharmaceuticals, medical
devices, and related aspects using this journal.
Scope
Categories• Translational Science• Regulatory Science
Including but not limited to:¾ Analytical Chemistry¾ Assay Development for Screening¾ Automation of screening (high throughput screening)¾ Clinical Research Efficiency¾ Collaboration and Partnerships¾ Compound/Library Management¾ Data Transparency and Sharing¾ De-risking Therapeutics Development¾ Early-Stage Drug Repurposing¾ Flexible Study Designs¾ Groundbreaking Efforts to Transform the Way Drugs and Medical
Devices are Developed, Evaluated, and Manufactured¾ Informatics¾ involvement and Ethical Aspects¾ Late-Stage Drug Repurposing¾ New Animal Models of Human Diseases¾ New Approaches to Assess the Safety, Efficacy, Quality, andPerformance of Medical Products¾ New Biomarkers and Clinical Application¾ New Concepts of Benefit/Risk Assessment, Submission, andApproval Strategies, Patient’s Involvement and Ethical Aspects¾ New Human Health and Ecological Risk Assessment Procedures
and Post-marketing Evaluation Method and Processes for Drugs andMedical Devices¾ New Methods/Approaches to Improve Patient Recruitment andRetention in Clinical Research Studies¾ New Methods/Approaches to Reduce Research Costs and Complexity¾ New Predictive Methods/Models for Efficacy Evaluation¾ New Predictive Methods/Models for Toxicity Evaluation¾ New Standards and Approaches to Facilitate Sound and Transparent
Regulatory Decision-making Regarding Drugs and Medical Devices¾ New Standards, Concepts, Proposals, and/or Regulations for Gene
Therapy, Cell Therapy, and Regenerative Medicine¾ Patient and Contact Registries¾ Probe Development and Lead Optimization¾ Translational Clinical Sciences from Animals to Humans¾ Target Identification and Validation
Sub-categories
One of the following sub-categories should be noted as the field of thepaper:
Biochemistry, O rganic Chemistry, Natural Product Chemistry, Herbal
Medicine, Metabolism, Neuroscience, Immunology/Allergy, Experimental
Animal, Cell Signaling, Stem Cell/iPS, Genome/Epigenome, Drug
Delivery System, Drug Metabolomics, Toxicology, Evaluation Study,
Public Health, Risk Assessment Study, and Epidemiology
Frequency of publication
TRS is issued quarterly, and the inaugural issue of TRS will be publishedin August 2019.

6

Ethical Treatment of Subjects
Submission of a manuscript implies that the authors warrant compliancewith institutional policies governing the ethical treatment of humansubjects and animals, and are ready to share the original approval
documents if so requested.
Human and animal rights
If the work involves the use of human subjects, the authors should ensurethat the work has been carried out in accordance with the International
Code of Medical Ethics of the World Medical Association, Inc.
(Declaration of Helsinki) for experiments involving humans and Uniform
Requirements for Manuscripts Submitted to Biomedical Journals. Authors
should include a statement in the manuscript that informed consent was
obtained for experimentation with human subjects. The privacy rights ofhuman subjects must always be observed.
All animal experiments should comply with the Law (or guidelines) for
the Humane Treatment and Management of Animals as well as Standards
Relating to the Care and Management of Laboratory Animals and Reliefof Pain. Such studies should be carried out in accordance with the official
guidelines for experimental animal treatment and reporting, as current in
the countries where the reporting manuscript originated. Examples of theseguidelines are the Guidelines for Proper Conduct of Animal Experiments
stipulated by the Science Council of Japan, Animals (Scientific Procedures)
Act 1986 and associated guidelines in the U.K., European Communities
Council Directive of 24 November 1986 (86/609/EEC), and National
Institutes of Health Guide for the Care and Use of Laboratory Animals(NIH Publications No. 8023, revised 1978). The authors should conformto the internationally accepted “3R” (Replacement, Reduction, andRefinement) principle in accordance with the Fundamental Guidelines for
Proper Conduct of Animal Experiment and Related Activities compiled by
the related ministries, and should clearly indicate in the manuscript thatsuch guidelines have been followed.
Types of Manuscript
O riginal articles (Full papers, Short communication), Letters, News,
Platform, and Review articles that are principally related to translationaland regulatory sciences and are unpublished and not being considered for
publication elsewhere can be accepted. Submitted manuscripts not rejected
at the first screening will undergo a peer-review process that occasionallycould require substantial revision and may last several months, dependingon the timeliness of author response. All manuscripts must be written ingood English (American or British usage is accepted, but not a mixture ofthese). Manuscripts are selected for publication according to an editorialassessment of their suitability and reports from referees. Papers are rejected
if the ethical treatment of subjects has not been appropriate.
Submission Declaration, Verification, and Fee
Submission of an article implies that the work described has not been
published previously (except in the form of an abstract or as part of apublished lecture or academic thesis or as an electronic preprint), that it
is not under consideration for publication elsewhere, that its publication
is approved by all authors and tacitly or explicitly by the responsible
authorities where the work was carried out, and that, if accepted, it
will not be published elsewhere in the same form, in English or in any
other language, including electronically without the written consent of
the copyright-holder. Written authorization by personal sources may berequired at the editor’s discretion.
The submission charge and publication fee are free as a temporary
arrangement.
Submission
All manuscripts must be submitted through e-mail: submission@cutrs.jp
Peer review
All contributions will be initially assessed by the editor for suitability forthe journal. Papers deemed suitable are then typically sent to a minimumof two independent expert reviewers to assess the scientific quality of thepaper. The editor is responsible for the final decision regarding acceptanceor rejection of articles. The editor’s decision is final.

Article Structure
Introduction
State the objectives of the work and provide an adequate background,avoiding a detailed literature survey or a summary of the results.
Material and methods
Provide sufficient details to allow the work to be reproduced by anindependent researcher. Methods that are already published should besummarized, with the reference indicated. If quoting directly from apreviously published method, use quotation marks and also cite the source.
Any modifications to existing methods should also be described.
Theory/calculation
A Theory section should extend, not repeat, the background to the article
already dealt with in the Introduction and lay the foundation for further
work. In contrast, a Calculation section represents a practical developmentfrom a theoretical basis.
Results
Results should be clear and concise.
Discussion
This section should explore the significance of the results of the work,
not repeat them. A combined Results and Discussion section is often
appropriate. Avoid extensive citations and discussion of publishedliterature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions
section, which may stand alone or form a subsection of a Discussion or
Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B,
etc. Formulae and equations in appendices should be given separate
numbering: Eq. (A. 1), Eq. (A. 2), etc.; in a subsequent appendix, Eq.
(B. 1) and so on. Similarly, for tables and figures: Table A. 1; Fig. A. 1, etc.
Abstract
A concise and factual abstract is required. The abstract should state briefly
the purpose of the research, the principal results, and major conclusions.
An abstract is often presented separately from the article, so it must beable to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Non-standard or uncommon
abbreviations should be avoided, but if essential, they must be defined attheir first mention in the abstract itself. The abstract should be fewer than
250 words.
Highlight
Highlight is mandatory for this journal. It consists of the significanceand core findings of the manuscript (maximum 150 words.) the highlightprovides readers with an at-a-glance overview of the main findings of yourmanuscript and lets them quickly identify what they want to read.
Keywords
Provide up to five keywords.
Abbreviations
Define abbreviations that are not standard in this field in a footnote tobe placed on the first page of the article. Such abbreviations that are
unavoidable in the abstract must be defined at their first mention there,
as well as in footnotes. Ensure consistency in abbreviations throughout
the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article
before the references and do not, therefore, include them on the title page
as a footnote to the title or otherwise. List here those individuals who
provided help during the research (e.g., providing language help, writing
assistance, or proofreading the article).
Role of the funding source
You are requested to identify who provided financial support for the
conduct of the research and/or preparation of the article and to briefly
describe the role of the sponsor(s), if any, in the study design; in thecollection, analysis, and interpretation of data; in the writing of the report;
and in the decision to submit the article for publication. If the funding
source(s) had no such involvement, then this should be stated.
Formatting of funding sources
List funding sources in this standard way to facilitate compliance tofunder’s requirements:
Funding: This work was supported by the National Institutes of Health[grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle,
WA [grant number zzzz]; and the United States Institutes of Peace [grant
number aaaa].
It is not necessary to include detailed descriptions of the program or type of
grants and awards. When funding is from a block grant or other resources
available to a university, college, or other research institution, submit
the name of the institute or organization that provided the funding. If nofunding has been provided for the research, please include the following
sentence: This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
Figure captions
Ensure that each illustration has a caption. A caption should comprise abrief title (not on the figure itself) and a description of the illustration. Keeptext in the illustrations themselves to a minimum but explain all symbols
and abbreviations used.
TablesPlease submit tables as editable text and not as images. Each term or phrase
should begin with a capital letter. Tables can be placed either next to therelevant text in the article or on separate page(s) at the end. Number tables
consecutively in accordance with their appearance in the text and place
any table notes below the table body. Reference to footnotes should bedesignated by symbols in the order a), b), c). Be sparing in the use oftables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules andshading in table cells.
Abbreviations, Units, and Nomenclature
Scientific terms for animals, plants, and microorganisms must be italicized.
Abbreviations should be written in parentheses after spelling out the termin full at the first appearance in the manuscript. Arabic numerals should
be used for quantities. Units and abbreviations should conform to thefollowing examples: M, mM, μM, N, %, m, cm, mm, μm, nm, pm, cm2,
l, ml, kg, g, mg, μg, ng, pg, hr, min, sec, msec, rpm, Hz, Bq, mBq, μBq,
kBq, cpm, dpm, ppm, °C, J, KJ, lux, CP E, LD. Nomenclature used in
the manuscript should be appropriately given in accordance with therules and guidelines of international nomenclature. Nomenclature used
for chemical compounds shall be in accordance with the nomenclaturerules formulated by International Union of Pure and Applied Chemistry(IUPAC). Alternatively, naming may conform to the nomenclature in theindex of Chemical Abstracts or the Ring index. The scientific name ofanimals used in animal experimentations should be given.
References
References should be cited in the text as numbers in square brackets in theorder of appearance (e.g., [1, 3–5, 7]). References should be listed in thereference list by these numbers. Only articles that have been published or
are in press should be included in the references. Unpublished results or
personal communications should be cited as such in the text.
The following are examples of References:
1. Beiser, J. A., Gustin, K. M., Pearce, M. B., Maines, T. R., Zeng, H.,
Pappas, C., Sun, X. S., Camey P. J., Villanueva, J. M., Stevens, J.,
Katz, J. M. and Tumpey, T. M. 2013. Pathogenesis and transmissionof avian influenza A (H7N9) virus in ferrets and mice. Nature 501:
556–559.
2. Hamm, L. L., Alpern, R. J. and P reisig, P . A. 2013. Cellularmechanisms of renal tubular acidification. pp. 1917–1978. In: Seidin
and Giebisch’s The Kidney, 5th ed. (Alperm, R. J., Caplan, M. J. andMoe, O. W. eds.), Elsevier, Amsterdam.
3. Sasaki, H., Sasaki, N., Nishino, T., Nagasaki, K., Kitamura, H.,
Torigoe, D. and Agui, T. 2014. Quantitative trait loci for resistanceto the congenital nephropathy in tensin 2-deficient mice. PLOS ONE
9: e99602.
4. Wild, D. G. 2013. The Immunoassay Handbook, 4th ed., Elsevier
Science & Technology, Oxford.

7

Editorial board
Editor-in-Chief
Yoshihiro YONEDA (National Institutes of Biomedical Innovation, Health and Nutrition)

Vice Editor-in-Chief
Hirosato KONDO (National Institutes of Biomedical Innovation, Health and Nutrition)
Masatoshi HORI (The University of Tokyo)

Editors
Biochemistry
Masaru TANOKURA (The University of Tokyo)
Masumi ETO (Okayama University of Science)

Organic Chemistry
Tomohiko OHWADA (The University of Tokyo)

Herbal Medicine
Tetsuro OIKAWA (Kitasato University)

Metabolism
Takahisa NAKAMURA (Cincinnati Children’s Hospital Medical Center)

Neuroscience
Shigeo TAKAMORI (Doshisha University)
Kenzo HIROSE (The University of Tokyo)
Shinichi SEKIZAWA (The University of Tokyo)

Immunology, Allergy
Osamu KAMINUMA (University of Yamanashi)
Takahisa MURATA (The University of Tokyo)
Koji MATSUSHIMA (Tokyo University of Science)

Experimental Animal
Hiromichi YONEKAWA (Tokyo Metropolitan Institute of Medical Science)
Wataru FUJII (The University of Tokyo)
Shigeru KAKUTA (The University of Tokyo)

Cell Signaling
Hidenori ICHIJO (The University of Tokyo)
Kosuke TAKEDA (Nagasaki University)
Masatoshi HORI (The University of Tokyo)

Stem Cells, iPSTakahiro IWAO (Nagoya City University)

Genome, Epigenome
Seungil RO (The University of Nevada)
Yukihide MOMOZAWA (RIKEN)
Satoshi TANAKA (The University of Tokyo)

DDS
Tong-Rong JAN (National Taiwan University)
Takashi INUI (Osaka Prefecture University)

Toxicology
Satoshi KITAJIMA (National Institute of Health Sciences)Tong-Rong JAN (National Taiwan University)

Regulatory Science (Evaluation, Policy)
Tsutomu KUROSAWA (Kagoshima University)
Takao YAMORI (Pharmaceuticals and Medical Devices Agency)
Yoshiaki UYAMA (Pharmaceuticals and Medical Devices Agency)

Drug Metabolism
Kazuaki SASAKI (Tokyo University of Agriculture and Technology)8